Pharmacokinetics of cefpirome in pediatric patients.
Cefpirome is a new investigational cephalosporin. We designed a study to determine the pharmacokinetics and tolerance of cefpirome in pediatric patients. A single dose of cefpirome was administered intravenously over 15 min to 18 patients (age 0.5 to 18 years). The doses were 10 mg/kg of body weight for five patients, 25 mg/kg of body weight for seven patients, and 50 mg/kg of body weight for six patients. Blood samples were collected at 0, 0.25, 0.5, 1, 3, 5, and 8 h after the dose, and cefpirome was measured by a high-performance liquid chromatography method. The maximum concentration in serum ranged from about 53.6 to 454 micrograms/ml after doses of 10 to 50 mg/kg. The total body clearance, apparent volume of distribution, and elimination half-life were 2.15 +/- 0.70 ml/min/kg, 0.32 +/- 0.32 liter/kg, and 1.8 +/- 1.3 h, respectively. No significant adverse effects were attributed to cefpirome. These data may be useful in conducting efficacy and safety studies of cefpirome in pediatric patients.
Nahata
M C
MC
College of Pharmacy, Ohio State University, Columbus 43210, USA.
Barson
W J
WJ
Puri
S K
SK
D000293:Adolescent; D002511:Cephalosporins / Q000493:pharmacokinetics*; D002648:Child; D002675:Child, Preschool; D006801:Humans; D007223:Infant; D008657:Metabolic Clearance Rate; D000097572:Cefpirome
D002511:Cephalosporins; D000097572:Cefpirome